Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
Process & Production
Return to: PBR Home | Production & Manufacturing | Process & Production

Process & Production

MacroGenics' IND for colorectal cancer drug candidate MGD007 gets FDA approval By PBR Staff Writer
US-based biopharmaceutical firm MacroGenics has received approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) to proceed with the Phase I human clinical trial for this drug candidate 'MGD007'.
Production & Manufacturing > Process & Production > News
Kinex announces allowance of IND application for KX2-391 ointment by USFDA Kinex Pharmaceuticals has announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months.
Production & Manufacturing > Process & Production > News Lightlake Therapeutics files IND application for Naloxone opioid overdose nasal spray By PBR Staff Writer
UK-based biopharmaceutical firm Lightlake Therapeutics has filed an investigational new drug application (IND) for its naloxone-based opioid overdose reversal nasal spray.
Production & Manufacturing > Process & Production > News
See more Process & Production news

Latest Process & Production News and Insight

View all Process & Production news or find news targeted to your interests
OPKO granted patent from US Patent & Trademark Office for RAYALDEE
OPKO Health, a multinational biopharmaceutical and diagnostics company, has announced that the United States Patent and Trademark Office granted OPKO a patent covering RAYALDEE, the company’s product to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Production & Manufacturing > Process & Production > News
FDA approves Avanir's Phase II trial of MDD candidate AVP-786
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted Avanir Pharmaceuticals' investigational new drug (IND) application for a Phase II trial evaluating the safety and efficacy of its next generation compound AVP-786.
Production & Manufacturing > Process & Production > News
ViaCyte files IND with FDA for new cell replacement therapy for type 1 diabetes
ViaCyte a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, announced that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes.
Production & Manufacturing > Process & Production > News
FDA accepts to review POZEN's NDA refiling for PA8140/PA32540 tablets
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted to review, the resubmission of US-based pharmaceutical firm POZEN's new drug application (NDA) for PA8140/PA32540 tablets.
Production & Manufacturing > Process & Production > News
FDA grants priority review for Medivir's sNDA for Olysio-sofosbuvir combination
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted a Priority Review designation to Swedish pharmaceutical firm Medivir's supplemental New Drug Application (sNDA) for the use of once-daily Olysio (simeprevir) in combination with sofosbuvir for 12 weeks treatment of adult patients with genotype 1 chronic hepatitis C.
Production & Manufacturing > Process & Production > News
Otsuka, Lundbeck file NDA for brexpiprazole to treat schizophrenia and MDD
By PBR Staff Writer
Japan-based Otsuka Pharmaceutical and Danish pharmaceutical firm Lundbeck have submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for brexpiprazole to treat schizophrenia as well as an adjunctive treatment of major depressive disorder (MDD).
Production & Manufacturing > Process & Production > News
FDA accepts to review Teva's NDA for Albuterol MDPI
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted to review Teva Pharmaceuticals' new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated dry-powder inhaler to treat or prevent bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.
Production & Manufacturing > Process & Production > News
Palatin Technologies gets notification of patent allowance on Melanocortin Receptor-1 specific peptides
Palatin Technologies, a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/910,422 (the '422 application).
Production & Manufacturing > Process & Production > News
Kythera gets FDA acceptance for ATX-101 new drug application
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted for filing Kythera Biopharmaceuticals' new drug application (NDA) for ATX-101 (deoxycholic acid).
Production & Manufacturing > Process & Production > News
Rosetta Genomics gets notice of allowance for US Patent to treat ovarian cancer
Rosetta Genomics, a developer and provider of microRNA-based molecular diagnostics and therapeutics, has announced receipt of a Notice of Allowance from the US Patent and Trademark Office (USPTO) for U.S. Patent Application No. 13/977,797, entitled "Compositions and Methods for Treatment of Ovarian Cancer." The patent relates to inhibition of miR-210 for the treatment of ovarian cancer.
Production & Manufacturing > Process & Production > News
View all Process & Production news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250